Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) traded down 6% on Tuesday . The stock traded as low as $1.84 and last traded at $1.89. 632,380 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 966,098 shares. The stock had previously closed at $2.01.
Several analysts recently weighed in on the stock. Zacks Investment Research raised shares of Ekso Bionics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. ValuEngine raised shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.
The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.73 and a current ratio of 6.09. The stock has a market capitalization of $120.41, a PE ratio of -2.03 and a beta of 2.01.
In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 3.32% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. National Planning Corp boosted its position in Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after acquiring an additional 286,492 shares during the last quarter. Carl Domino Inc boosted its position in Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after acquiring an additional 102,734 shares during the last quarter. Intellectus Partners LLC boosted its position in Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after acquiring an additional 5,294 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after acquiring an additional 176,197 shares during the last quarter. 6.22% of the stock is currently owned by institutional investors and hedge funds.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.